1541 — ImmuneOnco Biopharmaceuticals Shanghai Balance Sheet
0.000.00%
Last trade - 00:00- HK$3.31bn
- HK$3.38bn
- CNY0.39m
Annual balance sheet for ImmuneOnco Biopharmaceuticals Shanghai, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | — |
| Status: | Final | Final | Final |
| Cash | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 668 | 635 | 609 |
| Net Total Accounts Receivable | |||
| Net Total Receivables | 0.034 | 0.991 | 0.039 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 704 | 652 | 687 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 164 | 174 | 149 |
| Long Term Notes Receivable | |||
| Other Long Term Assets | |||
| Total Assets | 893 | 840 | 875 |
| Accounts Payable | |||
| Payable / Accrued | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 2,478 | 51.7 | 116 |
| Capital Lease Obligations | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 2,491 | 60.8 | 126 |
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | -1,598 | 779 | 748 |
| Total Liabilities & Shareholders' Equity | 893 | 840 | 875 |
| Total Common Shares Outstanding |